Daunorubicin Articles
AS1413 achieves 42% remission rate in AML
15 December 2008
Diatos acquires DaunoXome from Gilead for $4.7M
15 May 2006
APP buys Bigmar's European facility and products
2 August 2004
OSI acquires oncology assets from Gilead in $200 million deal
27 November 2001
SuperGen's leukemia drug cleared in USA
22 November 2001
Despite revenue rise, Gilead loss increases
1 May 2001
Gilead Sciences to merge with NeXstar
2 March 1999
Novartis' Exelon Cleared In First Major Market
14 May 1998
Excellent Year For The Biotechnology Industry
16 December 1996
Encouraging Results With NeXstar's DaunoXome
15 July 1996
Xenova Starts Trials Of Second Cancer Drug
17 June 1996
NeXstar's DaunoXome Sees US Launch
13 May 1996
USA Approves NeXstar's DaunoXome For KS
15 April 1996
DaunoXome Launches
1 April 1996
Sandoz MDR Drug Shows Promise In Early Trials
13 November 1995
NeXstar hears FDA news on DaunoXome
16 October 1995
Medi-Physics' Myoview approvable + other approvables
25 September 1995
Vestar Daunoxome patent
21 August 1995
FDA Panel Backs NeXstar's DaunoXome...
19 June 1995
New York stock comment
19 June 1995
NeXstar Gains First Approval For Daunoxome
12 June 1995
Chiron/ Ben Venue Acquisition
10 April 1995
CPAC Approves Six Drugs In Japan
3 April 1995
DaunoXome Results In Kaposi's Sarcoma
28 November 1994
Anticancer Drugs In Development In Japan
24 October 1994
VESTAR FILES PLA IN UK
11 July 1994
ENZON'S ONCASPAR APPROVED IN USA
14 February 1994
FDA PANEL REJECTS DAUNOXOME NDA
28 June 1993
VESTAR DAUNOXOME EARLY FILING SUPRISE
22 March 1993
Showing 1-31 of 31 articles
- 1
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
